An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)

• Status: Completed
• Trial end date: 2016-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a study of OZURDEX® use in clinical practice in patients with diabetic macular edema (DME).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: BB 1101; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate

Criteria

Inclusion Criteria:

• Diagnosis of DME in at least one eye treated OZURDEX® per clinical practice

Exclusion Criteria:

• None